Table 1:

Patient characteristics

	Vaccine + OPT-821 (N=68)	OPT-821 (N=68)
Age (years)
n	68	68
Mean (SD)	49.8 (13.25)	52.5 (15.24)
Sex - n (%)
Male	39 (57.4)	32 (47.1)
Female	29 (42.6)	36 (52.9)
Race - n (%)
American Indian or Alaska Native	1 (1.5)	0
Asian	4 (5.9)	3 (4.4)
Black or African American	1 (1.5)	3 (4.4)
White	62 (91.2)	61 (89.7)
Other	0	1 (1.5)
Ethnicity - n (%)
Hispanic or Latino	3 (4.4)	2 (2.9)
Not Hispanic or Latino	65 (95.6)	66 (97.1)
ECOG Performance Status– n (%)
0	57 (83.8)	48 (70.6)
1	11 (16.2)	20 (29.4)
Number of Metastases – n (%)
1 to 3	60 (88.2)	57 (83.8)
4 or more	8 (11.8)	11 (16.2)
Primary Tumor Grade - n (%)
High	62 (91.2)	56 (82.4)
Intermediate	5 (7.4)	9 (13.2)
Low	1 (1.5)	3 (4.4)
Primary Site of Original Disease – n (%)
Soft Tissue	35 (51.5%)	32 (47.1%)
Other	18 (26.5%)	20 (29.4%)
Bone	8 (11.8%)	6 (8.8%)
Abdomen	4 (5.9%)	7 (10.3%)
Lungs	1 (1.5%)	2 (2.9%)
Kidney	1 (1.5%)	1 (1.5%)
Head and Neck	1 (1.5%)	0
Metastatic Disease at time of Original Diagnosis – n (%)
Yes	13 (19.1%)	11 (16.2%)
No	55 (80.9%)	57 (83.8%)
Most Recent Disease-free Interval – n (%)
< 12 months	34 (50.0%)	33 (48.5%)
>= 12 months	28 (41.2%)	28 (41.2%)
Number of Relapses – n (%)
1	34 (50.0%)	36 (52.9%)
> 1	28 (41.2%)	25 (36.8%)
Prior Radiotherapy - n (%)
Yes	35 (51.5%)	34 (50.0%)
No	33 (48.5%)	34 (50.0%)
Prior Chemotherapy – n (%)
Yes	35 (51.5%)	37 (54.4%)
No	33 (48.5%)	31 (45.6%)
Tumor Histology - n (%)
Leiomyosarcoma (n=45)	17 (25%)	28 (41%)
Spindle Cell Sarcoma (n=19)	12 (18%)	7 (10%)
Pleomorphic Sarcoma (n=18)	9 (13%)	9 (13%)
Osteosarcoma (n=14)	7 (10%)	7 (10%)
Liposarcoma (n=12)	6 (9%)	6 (9%)
Synovial Sarcoma (n=12)	5 (7%)	7 (10%)
Other (n=16)	12 (18%)	4 (6%)